Evaluate and monitor ovarian cancer, usually epithelial subtype. Not recommended for monitoring breast cancer or germ tumors. Not a stand-alone test for ovarian cancer screening or diagnosis.
Quantitative Electrochemiluminescent Immunoassay
Within 24 hours
New York DOH Approval Status
Plasma separator tube or serum separator tube. Also acceptable: Green (lithium heparin), lavender (EDTA), or pink (K2EDTA, K3EDTA).
Allow specimen to clot completely at room temperature. Separate serum or plasma from cells ASAP or within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.5 mL)
Grossly hemolyzed specimens.
After separation from cells: Ambient: 5 days; Refrigerated: 5 days; Frozen: 24 weeks
Effective February 22, 2022
Less than or equal to 38 U/mL
The Roche CA 125 electrochemiluminescent immunoassay is used. Results obtained with different test methods or kits cannot be used interchangeably. The CA 125 test is used as an aid in monitoring response to therapy for patients with epithelial ovarian cancer. Serial testing for patient CA 125 values should be used in conjunction with other clinical methods for monitoring ovarian cancer. Patients with confirmed ovarian carcinoma may have pretreatment CA 125 values in the same range as healthy individuals. Elevations may be observed in patients with nonmalignant disease. Therefore, a CA 125 value, regardless of level, should not be interpreted as absolute evidence of the presence or absence of malignant disease.
|Component Test Code*||Component Chart Name||LOINC|
|0080462||Cancer Antigen 125||10334-1|
- CA 125
- CA 125 Tumor Marker
- CA-125 tumor marker
- CA125 concentration
- CA125 levels
- Cancer Ag 125
- Cancer antigen 125
- Carbohydrate Antigen 125
- OV Monitor
- Ovarian Cancer-Related Antibodies